Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Mehta

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Circulation. Cardiovascular Imaging|April 9, 2013
Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mappingDaniel M Sado, Steven K White, Stefan K Piechnik, et al.
Molecular Genetics and Metabolism|August 30, 2017
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physiciansAtul Mehta, Nadia Belmatoug, Bruno Bembi, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Heart (British Cardiac Society)|September 1, 2012
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and diseaseDaniel M Sado, Andrew S Flett, Sanjay M Banypersad, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|December 6, 2014
Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonanceSilvia Pica, Daniel M Sado, Viviana Maestrini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's diseaseRaquel Duran, Niccolo E Mencacci, Aikaterini V Angeli, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Circulation. Cardiovascular Imaging|April 9, 2013
Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mappingDaniel M Sado, Steven K White, Stefan K Piechnik, et al.
Molecular Genetics and Metabolism|August 30, 2017
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physiciansAtul Mehta, Nadia Belmatoug, Bruno Bembi, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Heart (British Cardiac Society)|September 1, 2012
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and diseaseDaniel M Sado, Andrew S Flett, Sanjay M Banypersad, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|December 6, 2014
Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonanceSilvia Pica, Daniel M Sado, Viviana Maestrini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's diseaseRaquel Duran, Niccolo E Mencacci, Aikaterini V Angeli, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Pageof 15